Generating solutions

Women with ovarian cancer have an overall survival rate of only six years, with the first of multiple recurrences happening between 12 and 18 months after detection. That is because ovarian cancer commonly presents at an advanced stage and has biologic resistance to conventional therapy. Once ovarian cancer is detected, there is an urgent need to better identify precision treatment options for each patient, based on their unique tumour characteristics. This pilot implementation project will use a suite of genomics testing—Comprehensive Genomic Profile—to more efficiently identify patients with one type of profile, homologous recombination deficiency, which are specific for the recently developed Poly(ADP-ribose) polymerase inhibitors (PARPi) treatment. It will integrate testing with an upgraded clinical and diagnostic reporting solution for genetic profiling of patient tumour information. As well as enhancing testing capacity, clinical implementation will improve treatment of cancer patients, optimize their care and enable more efficient use of resources in Saskatchewan’s healthcare system.